Live Breaking Biotech News and Articles

Biotech News Journal

Subscribe to Biotech News Journal: eMailAlertsEmail Alerts newslettersWeekly Newsletters
Get Biotech News Journal: homepageHomepage mobileMobile rssRSS facebookFacebook twitterTwitter linkedinLinkedIn


Biotech Authors: Greg Wind

Related Topics: Biotech News Journal, Government News, Pharmaceutical News, Market Research, Disability Nexus

News Feed Item

Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical

DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering.

600769

Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath is damaged because of an abnormal response by the immune system, which targets neurons within the central nervous system (CNS). It is a potentially debilitating disease in which the damage of the myelin sheath causes disruption in the communication and coordination functions of the body.

The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed in a patient with multiple sclerosis are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with the severe course of the disease can experience speech problems and movement problems.

Multiple sclerosis can be broadly classified into four types: relapsing-remitting multiple sclerosis, secondary-progressive multiple sclerosis, primary-progressive multiple sclerosis, and progressive-relapsing multiple sclerosis. On the basis of the route of drug administration, the Global Multiple Sclerosis Drugs market can be segmented into two: Oral Drugs, and Parenteral Drugs.

The analysts forecast the Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018.

This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis.

The report, the Global Multiple Sclerosis Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Multiple Sclerosis Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Product Profiles

05. Market Research Methodology

06. Introduction

07. Rate of Incidence and Prevalence

08. Market Segmentation by Molecule Type

09. Market Segmentation by Route of Administration

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

19. Key Vendor Analysis

20. Other Reports in this Series

Companies Mentioned:

  • Americas
  • APAC
  • EMEA Key Vendors
  • Bayer
  • Biogen Idec
  • Merck Serono
  • Novartis
  • Teva Pharmaceutical
  • AB Science
  • Abbvie
  • Acorda
  • Active Biotech
  • GlaxoSmithKline
  • Glenmark
  • Mitsubishi Tanabe
  • Opexa
  • Pfizer
  • Sanofi

For more information visit http://www.researchandmarkets.com/research/z9b74c/global_multiple

Media Contact: Laura Wood, +353-1-481-1716, [email protected]

SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.